Skip to Content


Implantation or Injectable Dosage Form New Animal Drugs; Ketamine Hydrochloride

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.

Start Printed Page 17283


Final rule.


The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original abbreviated new animal drug application (ANADA) filed by Vetrepharm Research, Inc. The ANADA provides for veterinary prescription use of an injectable solution of ketamine hydrochloride in cats and subhuman primates.


This rule is effective April 10, 2002.

Start Further Info


Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

End Further Info End Preamble Start Supplemental Information


Vetrepharm Research, Inc., 119 Rowe Rd., Athens, GA 30601, filed ANADA 200-257 that provides for veterinary prescription use of Ketamine HCL, an injectable solution of ketamine hydrochloride, in cats and subhuman primates for restraint.

ANADA 200-257 is approved as of November 9, 2001, and the regulations are amended in 21 CFR 522.1222a to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In addition, Vetrepharm Research, Inc., has not been previously listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for this sponsor.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part


End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for “Vetrepharm Research, Inc.” and in the table in paragraph (c)(2) by numerically adding an entry for “064847” to read as follows:

End Amendment Part
Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(1) * * *

Firm name and addressDrug labeler code
*         *         *         *         *         *         *
Vetrepharm Research, Inc., 119 Rowe Rd., Athens, ­ GA 30601064847
*         *         *         *         *         *         *

(2) * * *

Drug labeler codeFirm name and address
*         *         *         *         *         *         *
064847Vetrepharm Research, Inc., 119 Rowe Rd., Athens, GA 30601
*         *         *         *         *         *         *
Start Part


End Part

3. The authority citation for 21 CFR part 522 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

4. Section 522.1222a is revised to read as follows:

End Amendment Part

(a) Specifications. Each milliliter contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity.

(b) Sponsors. See Nos. 000010, 000074, 000856, 059130, 061690, 064408, and 064847 in § 510.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Cats—(i) Amount. 5 to 15 mg/pound body weight intramuscularly, depending on the effect desired.

(ii) Indications for use. For restraint or as the sole anesthetic agent in diagnostic or minor, brief surgical procedures that Start Printed Page 17284do not require skeletal muscle relaxation.

(2) Subhuman primates—(i) Amount. 3 to 15 mg/kilogram body weight intramuscularly, depending upon the species, general condition, and age of the subject.

(ii) Indications for use. For restraint.

Start Signature

Dated: February 27, 2002.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 02-8569 Filed 4-9-02; 8:45 am]